LRMR DCF Valuation - Larimar Therapeutics Inc

Dashboard Market News Investing Ideas Pricing

Watchlist Manager

Watchlist

Price: 3.47 USD 0.58%

Market Cap: $360.5m

	Larimar Therapeutics Inc NASDAQ:LRMR	US
	Emmi AG SIX:EMMN	CH
	TFF Pharmaceuticals Inc NASDAQ:TFFP	US
R	Rogaland Sparebank OSE:ROGS	NO
C	Campbell Soup Co XHAM:CSC	US
P	Primoris Services Corp NYSE:PRIM	US
A	Aptose Biosciences Inc NASDAQ:APTO	CA
	Ardmore Shipping Corp NYSE:ASC	BM
	Amerigo Resources Ltd TSX:ARG	CA
	Fox Factory Holding Corp NASDAQ:FOXF	US
	Eni SpA MIL:ENI	IT
M	Motus Holdings Ltd JSE:MTH	ZA
	AnaptysBio Inc NASDAQ:ANAB	US
	Consolidated Edison Inc NYSE:ED	US
	Babcock & Wilcox Enterprises Inc NYSE:BW	US
	Tetra Tech Inc NASDAQ:TTEK	US
	Margaret Lake Diamonds Inc OTC:KNXFF	CA
	Novo Nordisk A/S NYSE:NVO	DK
	Paychex Inc NASDAQ:PAYX	US
	ARC Resources Ltd TSX:ARX	CA
	Gecina SA OTC:GECFF	FR
S	Somboon Advance Technology PCL SET:SAT	TH
	AirIQ Inc XTSX:IQ	CA
I	Intrum AB F:IJU	SE

LRMR's DCF value cannot be reliably calculated.

Relative Valuation Wall Street Price Targets

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.